10-Q: SIGA Technologies Reports Q3 Loss Amid Mpox Trial Setbacks

SIGA Technologies reported a net loss in Q3 2025, driven by decreased product sales and increased R&D expenses, while year-to-date performance remained strong despite negative mpox clinical trial results.

Summary

• SIGA Technologies, Inc. reported a net loss of $6.37 million for the three months ended September 30, 2025, a significant decline from a net income of $1.34 million in the same period of 2024.
• Total revenues for Q3 2025 were $2.62 million, down from $10.01 million in Q3 2024, primarily due to lower product sales and supportive services.
• For the nine months ended September 30, 2025, net income increased to $28.71 million from $13.45 million in the prior year, with total revenues rising to $90.78 million from $57.25 million.
• Product sales and supportive services for the nine months ended September 30, 2025, reached $85.84 million, including $53.3 million of oral TPOXX and $25.8 million of IV TPOXX sales to the U.S. Government, and $5.8 million in international sales.
• Research and development expenses significantly increased to $7.05 million in Q3 2025 from $3.02 million in Q3 2024, and to $14.91 million for the nine months ended September 30, 2025, from $8.97 million in the prior year, mainly due to increased self-funded R&D activity.
• Cash and cash equivalents increased to $171.96 million as of September 30, 2025, from $155.40 million at December 31, 2024, with net cash provided by operating activities at $60.33 million for the nine-month period.
• The 19C BARDA Contract's total potential payments increased by $14.3 million for manufacturing support and $13.2 million for pediatric formulation development, bringing the total contemplated payments up to approximately $630 million.
• Clinical trials (PALM 007, STOMP, UNITY) evaluating TPOXX for mpox treatment did not meet their primary endpoints for statistically significant improvement in time to lesion resolution, though TPOXX maintained a safety profile comparable to placebo.
• The European Medicines Agency (EMA) initiated a referral procedure for Tecovirimat-SIGA following questions over its effectiveness in mpox treatment, while the MHRA reassessment is ongoing.
• The company is targeting a Supplemental New Drug Application (NDA) submission in 2026 for a smallpox post-exposure prophylaxis (PEP) indication for oral TPOXX, pending ongoing sample analyses.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While year-to-date financial performance is strong and BARDA contract value increased, the significant Q3 net loss and substantial revenue decline are concerning. More importantly, the negative results from multiple mpox clinical trials and the subsequent EMA review pose a significant challenge to TPOXX's growth beyond its core smallpox indication, impacting future revenue diversification and market expansion.

Positives

• Year-to-date net income significantly increased to $28.71 million for the nine months ended September 30, 2025, compared to $13.45 million in the same period of 2024.
• Year-to-date total revenues grew substantially to $90.78 million for the nine months ended September 30, 2025, up from $57.25 million in the prior year.
• Net cash provided by operating activities showed a strong positive swing, reaching $60.33 million for the nine months ended September 30, 2025, compared to a net cash outflow of $7.55 million in the prior year.
• Cash and cash equivalents increased to $171.96 million as of September 30, 2025, indicating a healthy liquidity position.
• The 19C BARDA Contract was increased by $14.3 million for manufacturing support and $13.2 million for pediatric formulation development, bringing the total potential payments to approximately $630 million.
• Oral TPOXX has received regulatory approvals from the European Medicines Agency (EMA), Health Canada, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for various orthopoxvirus indications.
• The 'One Big Beautiful Bill Act' (OBBBA) signed on July 4, 2025, allows for immediate expensing of domestic research and development expenditures and reinstatement of 100% bonus depreciation for qualified property, which is expected to benefit the company's tax position.

Negatives

• The company reported a net loss of $6.37 million for the three months ended September 30, 2025, a significant reversal from a net income of $1.34 million in Q3 2024.
• Total revenues for Q3 2025 decreased substantially to $2.62 million from $10.01 million in Q3 2024, primarily due to lower product sales.
• Operating expenses increased to $12.84 million in Q3 2025 from $9.47 million in Q3 2024, largely driven by a significant increase in research and development expenses.
• Research and development expenses increased by approximately $4.1 million in Q3 2025 and $5.9 million year-to-date, primarily due to increased self-funded activities.
• Clinical trials (PALM 007, STOMP, UNITY) evaluating TPOXX for mpox treatment did not meet their primary endpoints, indicating a lack of statistically significant efficacy for this indication.
• The European Medicines Agency (EMA) initiated a referral procedure for Tecovirimat-SIGA due to questions regarding its effectiveness in mpox treatment, which could impact its marketing authorization.
• Accumulated deficit increased to $(37.64) million as of September 30, 2025, from $(22.84) million at December 31, 2024.
• Total stockholders' equity decreased to $203.48 million as of September 30, 2025, from $215.80 million at December 31, 2024.

Risks

• The risk that the company may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms.
• The risk that the BARDA Contract is modified or canceled at the request or requirement of, or the company is not able to enter into new contracts to supply TPOXX to, the U.S. Government.
• The risk that the nascent international biodefense market does not develop to a degree that allows the company to continue to successfully market TPOXX internationally.
• The risk that potential products, including potential alternative uses or formulations of TPOXX, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, as evidenced by recent mpox trial results.
• The risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by actions or inaction of contract manufacturing organizations or other vendors.
• The risk that the company or its collaborators will not obtain or maintain appropriate or necessary governmental approvals to market products or uses, particularly concerning the EMA's review of Tecovirimat-SIGA for mpox.
• The risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection.
• The risk that regulatory requirements applicable to products may result in the need for further or additional testing or documentation, delaying or preventing needed approvals.
• The risk that changes in domestic or foreign economic and market conditions, including tariffs and trade policies, may affect the company's ability to advance research or affect its products adversely.
• The risk of disruptions to the supply chain for the manufacture of TPOXX, causing delays in R&D activities or government contracts.
• An extended U.S. Government shutdown could materially adversely affect the business, results of operations, and financial condition by delaying funding decisions, new contract awards, and contract modifications.

Future Outlook

The company is targeting a Supplemental New Drug Application (NDA) submission in 2026 for a smallpox post-exposure prophylaxis (PEP) indication for oral TPOXX, contingent on the results of ongoing sample analyses from immunogenicity trials. The company expects current manufacturing and delivery obligations to be recognized as revenues within the next 12 months, and research and development service obligations within the next three years. The EMA's referral procedure for Tecovirimat-SIGA's effectiveness in mpox and the ongoing MHRA reassessment could impact future marketing authorizations for this indication. The company believes ongoing mpox trials (Platinum-CAN, EPOXI) are likely to yield similar negative results to PALM007, STOMP, and UNITY.

Management Comments

• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report." Diem Nguyen, Ph.D., CEO
• "Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report." Diem Nguyen, Ph.D., CEO
• "The expense increase [in R&D] is primarily attributable to an increase in self-funded research and development activity." Management's Discussion and Analysis
• "We believe that our liquidity and capital resources will be sufficient to meet our anticipated requirements for at least the next twelve months from the issuance of these financial statements." Management's Discussion and Analysis

Industry Context

SIGA Technologies operates in the biodefense and pharmaceutical sectors, specializing in antiviral drugs for orthopoxviruses. The recent negative clinical trial results for TPOXX in mpox treatment, coupled with the EMA's referral procedure, highlight the challenges of expanding indications for existing drugs, especially for rare diseases where comprehensive efficacy data is difficult to obtain. The company's strong reliance on government procurement contracts, particularly with BARDA, provides a stable revenue base for its core smallpox indication, but growth opportunities are heavily dependent on successful R&D and regulatory approvals for new uses or formulations. The macroeconomic environment, including potential tariffs and government shutdowns, remains a relevant factor for companies with significant government contracts.

Comparison to Industry Standards

• The company's TPOXX product has received regulatory approvals from multiple international agencies (EMA, Health Canada, MHRA, PMDA) for orthopoxvirus indications, demonstrating a strong global presence for its core product.
• The EMA's decision to initiate a referral procedure for Tecovirimat-SIGA's effectiveness in mpox, following negative clinical trial results (PALM007, STOMP, UNITY), indicates that the product's performance for this specific indication did not meet the expected efficacy standards, contrasting with the initial exceptional circumstances marketing authorizations.
• The gross margin for the IV formulation of TPOXX under the BARDA contract is estimated to be less than 40%, which may be lower than typical margins for some specialized pharmaceutical products but is within a reasonable range for government contracts with specific manufacturing requirements.

Management Changes

Legal Proceedings

• The company may be involved in a variety of claims, suits, investigations, and proceedings arising from the ordinary course of business, including collections claims, breach of contract claims, labor and employment claims, and tax-related matters. Management believes the resolution of current pending matters will not have a material adverse effect on the business.

Related Party Transactions

• The company leases its corporate headquarters at 31 East 62nd Street, New York, NY, from MacAndrews & Forbes Incorporated (M&F) under a ten-year Office Lease agreement (New HQ Lease) entered into on May 26, 2017. Rent and ancillary services paid to M&F were $0.1 million for Q3 2025 and $0.3 million for the nine months ended September 30, 2025.
• An individual who was elected to the Board of Directors on June 13, 2023, provided consulting services to the company, receiving a monthly fee of $20,000 in 2023 and 2024. The company incurred $40,000 under this agreement during the two months ended February 28, 2025, prior to the individual's resignation from the Board on March 6, 2025.

Stakeholder Impact

• Shareholders: Impacted by the Q3 net loss and decreased revenue, but also by the strong year-to-date performance and the special cash dividend payment of $0.60 per share. The negative mpox trial results and EMA review could affect future growth prospects and stock valuation.
• Employees: Increased R&D expenses include higher compensation expense in connection with an increase in headcount, suggesting positive impact on employment.
• Customers (U.S. Government, international governments): Continued supply of TPOXX under BARDA and international contracts, with increased funding for manufacturing and pediatric formulation, ensures ongoing product availability for biodefense needs.
• Regulatory Authorities: The EMA's referral procedure for Tecovirimat-SIGA's mpox indication highlights ongoing scrutiny and the need for robust efficacy data for product approvals and maintenance of marketing authorizations.

Next Steps

• Targeting a Supplemental NDA submission in 2026 for a smallpox post-exposure prophylaxis (PEP) indication for oral TPOXX, pending ongoing sample analyses.
• Continue to monitor the EMA's referral procedure for Tecovirimat-SIGA regarding its effectiveness in mpox and the ongoing MHRA reassessment.
• Ongoing clinical trials (Platinum-CAN, EPOXI) for mpox are expected to close to enrollment this year, with results anticipated to be similar to previous negative trials.

Key Dates

Recommendation

SIGA Technologies presents a mixed financial picture. While year-to-date revenues and net income are robust, driven by strong government contracts for TPOXX, the third quarter saw a significant net loss and revenue decline. More critically, the repeated failures of TPOXX in mpox clinical trials and the subsequent EMA referral procedure cast a shadow on the company's ability to expand its product's indications and market reach beyond smallpox. The company's liquidity is strong, and the BARDA contract provides a stable foundation, but the lack of efficacy in mpox trials limits a key growth vector. Investors should hold, awaiting clearer indications on the future of TPOXX for mpox and progress on the smallpox PEP label expansion, while acknowledging the stability provided by existing government contracts.

Keywords

TPOXX, smallpox, mpox, BARDA contract, antiviral, biodefense, pharmaceutical, SEC filing, quarterly report, clinical trials, regulatory approval, government contracts, financial results, research and development